Top

Published in:

Open Access 01-12-2023 | Gentamicin | Research

Can platelet-rich fibrin act as a natural carrier for antibiotics delivery? A proof-of-concept study for oral surgical procedures

Authors: Francesco Bennardo, Luca Gallelli, Caterina Palleria, Manuela Colosimo, Leonzio Fortunato, Giovambattista De Sarro, Amerigo Giudice

Published in: BMC Oral Health | Issue 1/2023

Abstract

Objectives

Evaluate the role of platelet-rich fibrin (PRF) as a natural carrier for antibiotics delivery through the analysis of drug release and antimicrobial activity.

Materials and methods

PRF was prepared according to the L-PRF (leukocyte- and platelet-rich fibrin) protocol. One tube was used as control (without drug), while an increasing amount of gentamicin (0.25 mg, G1; 0.5 mg, G2; 0.75 mg, G3; 1 mg, G4), linezolid (0.5 mg, L1; 1 mg, L2; 1.5 mg, L3; 2 mg, L4), vancomycin (1.25 mg, V1; 2.5 mg, V2; 3.75 mg, V3; 5 mg, V4) was added to the other tubes. At different times the supernatant was collected and analyzed. Strains of E. coli, P. aeruginosa, S. mitis, H. influenzae, S. pneumoniae, S. aureus were used to assess the antimicrobial effect of PRF membranes prepared with the same antibiotics and compared to control PRF.

Results

Vancomycin interfered with PRF formation. Gentamicin and linezolid did not change the physical properties of PRF and were released from membranes in the time intervals examined. The inhibition area analysis showed that control PRF had slight antibacterial activity against all tested microorganisms. Gentamicin-PRF had a massive antibacterial activity against all tested microorganisms. Results were similar for linezolid-PRF, except for its antibacterial activity against E. coli and P. aeruginosa that was comparable to control PRF.

Conclusions

PRF loaded with antibiotics allowed the release of antimicrobial drugs in an effective concentration. Using PRF loaded with antibiotics after oral surgery may reduce the risk of post-operative infection, replace or enhance systemic antibiotic therapy while preserving the healing properties of PRF. Further studies are needed to prove that PRF loaded with antibiotics represents a topical antibiotic delivery tool for oral surgical procedures.

World Health Organization (2020) Antimicrobial resistance. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Accessed 18 Apr 2021

Majumder MAA, Singh K, Hilaire MG-S, et al. Tackling antimicrobial resistance by promoting antimicrobial stewardship in medical and allied health professional curricula. Expert Rev Anti Infect Ther. 2020;18:1245–58. https://doi.org/10.1080/14787210.2020.1796638.CrossRefPubMed

Goff DA, Mangino JE, Glassman AH, et al. Review of guidelines for dental antibiotic prophylaxis for prevention of endocarditis and prosthetic joint infections and need for dental stewardship. Clin Infect Dis. 2020;71:455–62. https://doi.org/10.1093/cid/ciz1118.CrossRefPubMed

Kelly SA, Rodgers AM, O’Brien SC, et al. Gut check time: antibiotic delivery strategies to reduce antimicrobial resistance. Trends Biotechnol. 2020;38:447–62. https://doi.org/10.1016/j.tibtech.2019.10.008.CrossRefPubMed

Drury JL, Mooney DJ. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials. 2003;24:4337–51. https://doi.org/10.1016/S0142-9612(03)00340-5.CrossRefPubMed

Nandi SK, Mukherjee P, Roy S, et al. Local antibiotic delivery systems for the treatment of osteomyelitis—a review. Mater Sci Eng C. 2009;29:2478–85. https://doi.org/10.1016/j.msec.2009.07.014.CrossRef

Wang Q, Chen C, Liu W, et al. Levofloxacin loaded mesoporous silica microspheres/nano-hydroxyapatite/polyurethane composite scaffold for the treatment of chronic osteomyelitis with bone defects. Sci Rep. 2017;7:41808. https://doi.org/10.1038/srep41808.CrossRefPubMedPubMedCentral

Zilberman M, Elsner J. Antibiotic-eluting medical devices for various applications. J Control Release. 2008;130:202–15. https://doi.org/10.1016/j.jconrel.2008.05.020.CrossRefPubMed

Lu Y, Hu Q, Jiang C, Gu Z. Platelet for drug delivery. Curr Opin Biotechnol. 2019;58:81–91. https://doi.org/10.1016/j.copbio.2018.11.010.CrossRefPubMed

10.

Spicer PP, Mikos AG. Fibrin glue as a drug delivery system. J Control Release. 2010;148:49–55. https://doi.org/10.1016/j.jconrel.2010.06.025.CrossRefPubMedPubMedCentral

11.

Yoshida H, Yamaoka Y, Shinoyama M, Kamiya A. Novel drug delivery system using autologous fibrin glue. release properties of anti-cancer drugs. Biol Pharm Bull. 2000;23:371–4. https://doi.org/10.1248/bpb.23.371.CrossRefPubMed

12.

Miron RJ, Fujioka-Kobayashi M, Bishara M, et al. Platelet-rich fibrin and soft tissue wound healing: a systematic review. Tissue Eng B Rev. 2017;23:83–99. https://doi.org/10.1089/ten.teb.2016.0233.CrossRef

13.

Bennardo F, Liborio F, Barone S, et al. Efficacy of platelet-rich fibrin compared with triamcinolone acetonide as injective therapy in the treatment of symptomatic oral lichen planus: a pilot study. Clin Oral Investig. 2021. https://doi.org/10.1007/s00784-020-03702-w.CrossRefPubMed

14.

Rechichi M, Ferrise M, Romano F, et al. Autologous platelet-rich plasma in the treatment of refractory corneal ulcers: a case report. Am J Ophthalmol Case Rep. 2020;20:100838. https://doi.org/10.1016/j.ajoc.2020.100838.CrossRefPubMedPubMedCentral

15.

Romano F, Paolino FM, Rizzo BA, et al. The use of growth factors, CD34 + cells and fibrin for the management of chronic venous ulcers. Int Wound J. 2016;13:1011–3. https://doi.org/10.1111/iwj.12500.CrossRefPubMed

16.

Egle K, Salma I, Dubnika A. From blood to regenerative tissue: how autologous platelet-rich fibrin can be combined with other materials to ensure controlled drug and growth factor release. Int J Mol Sci. 2021;22:11553. https://doi.org/10.3390/ijms222111553.CrossRefPubMedPubMedCentral

17.

Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27:158–67. https://doi.org/10.1016/j.tibtech.2008.11.009.CrossRefPubMed

18.

Choukroun J, Adda F, Schoeffler C, Vervelle A. Une opportunite en paro-implantologie: Le PRF. Implantodontie. 2001;42:55–62.

19.

Bielecki TM, Gazdzik TS, Arendt J, et al. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances. J Bone Joint Surg Br. 2007;89B:417–20. https://doi.org/10.1302/0301-620X.89B3.18491.CrossRef

20.

Bielecki T, Gazdzik TS. Antimicrobial activity of platelet-rich gel after antibiotic administration—a preliminary report. Orthop Proc Br Editor Soc Bone Jt Surg. 2009;91:131.

21.

Polak D, Clemer-Shamai N, Shapira L. Incorporating antibiotics into platelet-rich fibrin: a novel antibiotics slow-release biological device. J Clin Periodontol. 2019;46:241–7. https://doi.org/10.1111/jcpe.13063.CrossRefPubMed

22.

Siawasch SAM, Andrade C, Castro AB, et al. Impact of local and systemic antimicrobials on leukocyte- and platelet rich fibrin: an in vitro study. Sci Rep. 2022;12:2710. https://doi.org/10.1038/s41598-022-06473-4.CrossRefPubMedPubMedCentral

23.

Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45:493–6.CrossRefPubMed

24.

Weinstein MP, et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clin Lab Stand Inst. 2018;11:112.

25.

Fortunato L, Barone S, Bennardo F, Giudice A. Management of facial pyoderma gangrenosum using platelet-rich fibrin: a technical report. J Oral Maxillofac Surg. 2018. https://doi.org/10.1016/j.joms.2018.01.012.CrossRefPubMed

26.

Giudice A, Esposito M, Bennardo F, et al (2019) Dental extractions for patients on oral antiplatelet: a within-person randomised controlled trial comparing haemostatic plugs, advanced-plateletrich fibrin (A-PRF+) plugs, leukocyte- and plateletrich fibrin (L-PRF) plugs and suturing alone. Eur J Oral Implantol 12

27.

Fortunato L, Bennardo F, Buffone C, Giudice A. Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review. J Cranio-Maxillofacial Surg. 2020. https://doi.org/10.1016/j.jcms.2020.01.014.CrossRef

28.

Bennardo F, Bennardo L, Del Duca E, et al. Autologous platelet-rich fibrin injections in the management of facial cutaneous sinus tracts secondary to medication-related osteonecrosis of the jaw. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13334.CrossRefPubMedPubMedCentral

29.

Karan NB, Aricioğlu B. Assessment of bone healing after mineral trioxide aggregate and platelet-rich fibrin application in periapical lesions using cone-beam computed tomographic imaging. Clin Oral Investig. 2020;24:1065–72. https://doi.org/10.1007/s00784-019-03003-x.CrossRefPubMed

30.

Miron RJ, Moraschini V, Fujioka-Kobayashi M, et al. Use of platelet-rich fibrin for the treatment of periodontal intrabony defects: a systematic review and meta-analysis. Clin Oral Investig. 2021;25:2461–78. https://doi.org/10.1007/s00784-021-03825-8.CrossRefPubMedPubMedCentral

31.

Brancaccio Y, Antonelli A, Barone S, et al. Evaluation of local hemostatic efficacy after dental extractions in patients taking antiplatelet drugs: a randomized clinical trial. Clin Oral Investig. 2020. https://doi.org/10.1007/s00784-020-03420-3.CrossRefPubMed

32.

Miron RJ, Zhang Y. Autologous liquid platelet rich fibrin: a novel drug delivery system. Acta Biomater. 2018;75:35–51. https://doi.org/10.1016/j.actbio.2018.05.021.CrossRefPubMed

33.

McLaren AC. Alternative materials to acrylic bone cement for delivery of depot antibiotics in orthopaedic infections. Clin Orthop Relat Res. 2004;427:101–6. https://doi.org/10.1097/01.blo.0000143554.56897.26.CrossRef

34.

Stevens CM, Tetsworth KD, Calhoun JH, Mader JT. An articulated antibiotic spacer used for infected total knee arthroplasty: a comparative in vitro elution study of Simplex® and Palacos® bone cements. J Orthop Res. 2005;23:27–33. https://doi.org/10.1016/j.orthres.2004.03.003.CrossRefPubMed

35.

Antoci V, Adams CS, Hickok NJ, et al. Antibiotics for local delivery systems cause skeletal cell toxicity in vitro. Clin Orthop Relat Res. 2007;462:200–6. https://doi.org/10.1097/BLO.0b013e31811ff866.CrossRefPubMed

36.

Gessmann J, Seybold D, Ayami F, et al. Peripheral blood plasma clot as a local antimicrobial drug delivery matrix. Tissue Eng A. 2018;24:809–18. https://doi.org/10.1089/ten.tea.2017.0319.CrossRef

37.

Duewelhenke N, Krut O, Eysel P. Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrob Agents Chemother. 2007;51:54–63. https://doi.org/10.1128/AAC.00729-05.CrossRefPubMed

38.

Fischer AB. Gentamicin as a bactericidal antibiotic in tissue culture. Med Microbiol Immunol. 1975;161:23–39. https://doi.org/10.1007/BF02120767.CrossRefPubMed

39.

Edin ML, Miclau T, Lester GE, et al (1996) Effect of cefazolin and vancomycin on osteoblasts in vitro. Clin Orthop Relat Res 245–51

40.

Wang S, Li Y, Li S, et al. Platelet-rich plasma loaded with antibiotics as an affiliated treatment for infected bone defect by combining wound healing property and antibacterial activity. Platelets. 2020. https://doi.org/10.1080/09537104.2020.1759792.CrossRefPubMedPubMedCentral

41.

Ercan E, Suner SS, Silan C, et al. Titanium platelet–rich fibrin (T-PRF) as high-capacity doxycycline delivery system. Clin Oral Investig. 2022. https://doi.org/10.1007/s00784-022-04510-0.CrossRefPubMed

42.

Williams L, Domen R. Vancomycin-induced red cell aggregation. Transfusion. 1989;29:23–6. https://doi.org/10.1046/j.1537-2995.1989.29189101158.x.CrossRefPubMed

43.

Knafl D, Thalhammer F, Vossen MG. In-vitro release pharmacokinetics of amikacin, teicoplanin and polyhexanide in a platelet rich fibrin—layer (PRF)—a laboratory evaluation of a modern, autologous wound treatment. PLoS ONE. 2017;12:e0181090. https://doi.org/10.1371/journal.pone.0181090.CrossRefPubMedPubMedCentral

44.

Mamajiwala AS, Sethi KS, Raut CP, et al. Impact of different platelet-rich fibrin (PRF) procurement methods on the platelet count, antimicrobial efficacy, and fibrin network pattern in different age groups: an in vitro study. Clin Oral Investig. 2020;24:1663–75. https://doi.org/10.1007/s00784-019-03022-8.CrossRefPubMed

45.

Ghanaati S, Booms P, Orlowska A, et al. Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. J Oral Implantol. 2014;40:679–89. https://doi.org/10.1563/aaid-joi-D-14-00138.CrossRefPubMed

46.

Kubesch A, Barbeck M, Al-Maawi S, et al. A low-speed centrifugation concept leads to cell accumulation and vascularization of solid platelet-rich fibrin: an experimental study in vivo. Platelets. 2019;30:329–40. https://doi.org/10.1080/09537104.2018.1445835.CrossRefPubMed

47.

Miron RJ, Xu H, Chai J, et al. Comparison of platelet-rich fibrin (PRF) produced using 3 commercially available centrifuges at both high (~ 700 g) and low (~ 200 g) relative centrifugation forces. Clin Oral Investig. 2020;24:1171–82. https://doi.org/10.1007/s00784-019-02981-2.CrossRefPubMed

48.

Fujioka-Kobayashi M, Kono M, Katagiri H, et al. Histological comparison of Platelet rich fibrin clots prepared by fixed-angle versus horizontal centrifugation. Platelets. 2021;32:413–9. https://doi.org/10.1080/09537104.2020.1754382.CrossRefPubMed

49.

Feng M, Wang Y, Zhang P, et al. Antibacterial effects of platelet-rich fibrin produced by horizontal centrifugation. Int J Oral Sci. 2020;12:32. https://doi.org/10.1038/s41368-020-00099-w.CrossRefPubMedPubMedCentral

50.

Miron RJ, Horrocks NA, Zhang Y, et al. Extending the working properties of liquid platelet-rich fibrin using chemically modified PET tubes and the Bio-Cool device. Clin Oral Investig. 2022;26:2873–8. https://doi.org/10.1007/s00784-021-04268-x.CrossRefPubMed

51.

Miron RJ, Dham A, Dham U, et al. The effect of age, gender, and time between blood draw and start of centrifugation on the size outcomes of platelet-rich fibrin (PRF) membranes. Clin Oral Investig. 2019;23:2179–85. https://doi.org/10.1007/s00784-018-2673-x.CrossRefPubMed

52.

Wei Y, Cheng Y, Wang Y, et al. The effect of resting and compression time post-centrifugation on the characteristics of platelet rich fibrin (PRF) membranes. Clin Oral Investig. 2022. https://doi.org/10.1007/s00784-022-04496-9.CrossRefPubMed

53.

Del FM, Bortolin M, Taschieri S, et al. Antimicrobial properties of platelet-rich preparations. A systematic review of the current pre-clinical evidence. Platelets. 2016;27:276–85. https://doi.org/10.3109/09537104.2015.1116686.CrossRef

54.

Schuetz AN. Antimicrobial resistance and susceptibility testing of anaerobic bacteria. Clin Infect Dis. 2014;59:698–705. https://doi.org/10.1093/cid/ciu395.CrossRefPubMed

55.

Elbehwashy MT, Hosny MM, Elfana A, et al. Clinical and radiographic effects of ascorbic acid-augmented platelet-rich fibrin versus platelet-rich fibrin alone in intra-osseous defects of stage-III periodontitis patients: a randomized controlled clinical trial. Clin Oral Investig. 2021;25:6309–19. https://doi.org/10.1007/s00784-021-03929-1.CrossRefPubMedPubMedCentral

56.

Asher R, Oren F, Meir T, et al. Tranexamic acid integrated into platelet-rich fibrin produces a robust and resilient antihemorrhagic biological agent: a human cohort study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022. https://doi.org/10.1016/j.oooo.2022.03.006.CrossRefPubMed

57.

Mohsen S, Dickinson JA, Somayaji R. Update on the adverse effects of antimicrobial therapies in community practice. Can Fam Physician. 2020;66:651–9.PubMedPubMedCentral

58.

Brooks BD, Brooks AE. Therapeutic strategies to combat antibiotic resistance. Adv Drug Deliv Rev. 2014;78:14–27. https://doi.org/10.1016/j.addr.2014.10.027.CrossRefPubMed

59.

Miller YW, Eady EA, Lacey RW, et al. Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother. 1996;38:829–37. https://doi.org/10.1093/jac/38.5.829.CrossRefPubMed

60.

Gaynor BD. Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br J Ophthalmol. 2005;89:1097–9. https://doi.org/10.1136/bjo.2005.068981.CrossRefPubMedPubMedCentral

Title: Can platelet-rich fibrin act as a natural carrier for antibiotics delivery? A proof-of-concept study for oral surgical procedures
Authors: Francesco Bennardo
Luca Gallelli
Caterina Palleria
Manuela Colosimo
Leonzio Fortunato
Giovambattista De Sarro
Amerigo Giudice
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Gentamicin
Antibiotic
Linezolid
Vancomycin
Pseudomonas Aeruginosa
Published in: BMC Oral Health / Issue 1/2023
Electronic ISSN: 1472-6831
DOI: https://doi.org/10.1186/s12903-023-02814-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Can platelet-rich fibrin act as a natural carrier for antibiotics delivery? A proof-of-concept study for oral surgical procedures

Abstract

Objectives

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

The effect of water storage on nanoindentation creep of various CAD-CAM composite blocks

The effect of bromelain in periodontal surgery: a double-blind randomized placebo-controlled trial

Prevalence of dental caries in pregnant Colombian women and its associated factors

Oral status and affecting factors in Iranian ICU patients: a cross-sectional study

The global prevalence of oral leukoplakia: a systematic review and meta-analysis from 1996 to 2022

Identification of the inferior alveolar canal using cone-beam computed tomography vs. panoramic radiography: a retrospective comparative study